What happened with ILMN today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Illumina helps research laboratories, drug developers and clinical laboratories read and analyze genetic material. Customers buy sequencing instruments such as NovaSeq X, then purchase reagents, flow cells and sample-preparation kits to process samples. These consumables generate most of its revenue, so the business depends heavily on customers continuing to use its systems, not just buying new machines. Sequencing dominates the business; microarrays, which test genetic variation, are a smaller activity. Illumina also sells analysis tools and provides instrument support and sequencing services.
Life-sciences research is its historically core market, with demand supported by public and private research funding. Customers also use its products in cancer, inherited-disease and reproductive-health applications. A growing share of revenue comes from a small number of large, centralized laboratories, making their purchasing decisions increasingly important.
Clinical use has limits: products labeled for research use only are not intended for diagnostic procedures, and Illumina may not promote them for that purpose. Products intended for diagnosis may require regulatory clearance or approval before marketing. Sequencing-instrument exports to Chinese companies can resume, but each transaction remains subject to case-by-case approval by Chinese authorities.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Illumina’s results hinge on demand for sequencing consumables and platform competition from companies absent from this list, including Oxford Nanopore, MGI and privately held Element Biosciences.
Pacific Biosciences competes with Illumina for genomic research and clinical laboratories’ spending on sequencing instruments and repeat purchases of consumables. Watch sales of its HiFi long-read instruments and reagents for signs of competition for those laboratories’ sequencing work.
Thermo Fisher Scientific competes with Illumina for research and clinical laboratories’ sequencing work by selling Ion Torrent sequencing platforms and the reagents used with them.
10x Genomics, Inc. helps generate demand for Illumina sequencing and consumables: it sells researchers tools that prepare individual cells for sequencing-based analysis.
Natera depends on Illumina sequencers and reagents to deliver molecular tests sold directly and through laboratory partners, yet competes with Illumina’s Verinata business in prenatal testing. Activity in Panorama, Horizon, Signatera and Prospera is worth watching because these tests are validated only on Illumina’s platform.
GRAIL, Inc. buys Illumina sequencing equipment and reagents for its cancer-related work, including research tools used by oncology and biopharma partners. Its oncology revenue also carries a royalty obligation to Illumina, suspended until December 24, 2026, or an earlier change of control, making that revenue worth watching beyond equipment purchases.
Guardant Health’s cancer testing generates sequencing demand for Illumina, its sole supplier of sequencers and their maintenance and repair. Watch testing activity for hospitals, cancer centers and biopharma customers rather than treating all of Guardant’s data and licensing revenue as sequencing demand.
Twist Bioscience Corporation competes with Illumina to sell laboratories products that prepare samples for sequencing, while supporting sequencing work at shared customers. Its sequencing sample-preparation business is the relevant area to watch, rather than its broader synthetic-DNA business.
QIAGEN competes with Illumina for research and molecular diagnostic laboratories’ spending on preparing samples and analyzing genomic information. Its consumables business is worth watching for laboratory testing activity, though the overlap is in these workflows rather than sequencing instruments alone.
Tempus AI buys sequencers and laboratory reagents primarily from Illumina to provide research and clinical genomic testing to healthcare and life-sciences customers. Watch its Diagnostics testing activity for sequencing demand; the supply agreement requires neither minimum hardware orders nor exclusive use of Illumina.
Caris Life Sciences, Inc. buys Illumina sequencers and laboratory materials to provide tissue- and blood-based cancer profiling to clinical, academic and biopharma customers. Activity in MI Profile and Caris Assure is the relevant demand signal, but its Illumina agreement has no minimum purchase requirement.
GeneDx Holdings Corp. buys Illumina sequencing inputs to produce rare-disease diagnostic reports using exome and genome sequencing, with payment from insurers, patients and healthcare clients. Its diagnostic testing activity is the demand signal to watch; switching laboratory suppliers can require workflow changes and test revalidation.
Agilent Technologies shares laboratory customers with Illumina, selling genomics tools and consumables to research and diagnostic labs that buy Illumina sequencing systems and reagents. Its CrossLab consumables can sell regardless of a laboratory’s instrument choice, so their demand does not by itself show which sequencing platform is winning.
CareDx, Inc. buys Illumina instruments and reagents for transplant testing and commercializes Illumina’s licensed sequencing product line for transplantation diagnostics. Watch its testing for heart, kidney and lung recipients and its donor-recipient matching products for activity in this specialized market.
Illumina Inc earningsThis company
Illumina gets most of its revenue from sequencing consumables, and this report will show whether customers moving to NovaSeq X are still driving repeat purchases and whether instrument sales are keeping pace.
Read consumables sales alongside instrument sales. Growing consumables with steadier instrument sales would show that both repeat use of installed systems and new shipments are supporting Illumina. Growing consumables but falling instrument sales would mean existing customers’ repeat purchases are carrying revenue while demand for new systems remains weak. If both weaken, the pressure is broader across demand or shipments.
Pacific Biosciences of California, Inc. earningsPACB
PacBio’s report will show whether labs are buying more HiFi sequencers and reagents, offering Illumina a signal of how much a rival is competing for sequencing budgets.
Read HiFi instrument sales alongside reagent sales. Growth in both would show PacBio selling systems and generating follow-on consumables purchases, evidence that labs are assigning more sequencing work to this competing platform. Weakness in both would offer less evidence of competitive gains, but would not establish that Illumina won those orders.
Guardant Health, Inc. earningsGH
Guardant Health’s report will show how its cancer-testing activity is changing, a demand signal for the sequencing systems and consumables it gets from Illumina.
Focus on cancer-testing activity; Guardant’s data and licensing revenue is not all sequencing demand. More testing would point to greater sequencing needs at a customer that relies on Illumina as its sole supplier of sequencers and their maintenance and repair. Less testing would weaken that signal, but the report alone cannot show how many systems or consumables Illumina actually sold.
Natera, Inc. earningsNTRA
Natera’s report will show activity in tests that use Illumina’s platform and how the two companies are competing in prenatal testing.
Look at Natera’s testing activity, especially changes in its prenatal test Panorama. More activity overall would support continued use of Illumina’s platform; faster growth in Panorama could also mean Natera is competing for business in the prenatal market where Illumina’s Verinata operates. Weaker activity would weaken both signals, and Natera’s growth alone would not prove that Illumina’s related revenue is rising.
GRAIL, Inc. earningsGRAL
GRAIL’s report will show changes in oncology revenue, the potential base for royalties to Illumina after the stated suspension ends.
Watch GRAIL’s oncology revenue, keeping in mind that this report comes before the stated suspension ends on December 24, 2026. Higher revenue would provide a larger potential base if the royalty obligation resumes under its terms; lower revenue would provide a smaller base. The report does not show that Illumina received royalties during the suspension, and the materials give no rate for calculating an amount.
